Platinum-Based Treatment for Well- and Poorly Differentiated Pancreatic Neuroendocrine Neoplasms. Issue 2 (February 2021)

• Record Type: Journal Article
• Authors: Pulvirenti, Alessandra; Raj, Nitya; Cingarlini, Sara; Pea, Antonio; Tang, Laura H.; Luchini, Claudio; Chou, Joanne F.; Grego, Elisabetta; Marinova, Ioana; Capanu, Marinela; Landoni, Luca; Scarpa, Aldo; Allen, Peter J.; Klimstra, David S.; Reidy-Lagunes, Diane L.
• Is Part Of: Pancreas. Volume 50:Issue 2(2021)
• Publication Date: 2021-02
• Subjects: pancreatic neuroendocrine tumor -- PanNEC -- PanNET -- platinum-based treatment -- poorly differentiated neuroendocrine tumor; Pancreas -- Diseases -- Periodicals; Pancreas -- Periodicals; Neuroendocrine tumors -- Periodicals; 616.37005
• DOI: 10.1097/MPA.0000000000001740
• Languages: English
• ISSNs: 0885-3177

Abstract

Abstract : Objectives: Pancreatic neuroendocrine neoplasms include well-differentiated tumors (PanNETs) and poorly differentiated carcinomas (PanNECs). Previous reports suggested a role for platinum-based therapy largely in PanNEC. We sought to investigate the role of platinum-based therapy in pancreatic neuroendocrine neoplasms regardless of tumor grade and differentiation. Methods: Patients with pancreatic neuroendocrine neoplasms treated with platinum-based therapy at Memorial Sloan Kettering (1994–2016) and Verona University Hospital (2008–2016) were retrospectively identified. Response to treatment by RECIST v1.1, overall survival, and progression-free survival were defined. Among patients with available tissue, DAXX, ATRX, Rb, and p53 expression was evaluated to support the histologic grade of differentiation. Results: Fifty PanNETs, 29 PanNECs, and 22 high-grade tumors with undeterminable differentiation were included. No patients achieved complete response. Overall rate of partial response was 31%, 41% for PanNEC, and 20% for PanNETs. Among PanNETs, partial response was achieved in 33% of G1 (2/6), 10% of G2 (2/19), and 24% of G3 (6/25) tumors. Median overall survival was 29.3 months for PanNETs and 10.9 months for PanNEC ( P < 0.001). There was no significant difference in median progression-free survival ( P = 0.2). Conclusions: Platinum-based therapies demonstrated increased activity in PanNEC; however, promising efficacy was also observed in PanNETs, irrespective of grade. Abstract : Supplemental digital content is available in the text.